Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholestatic jaundice during lovastatin medication].

U Spreckelsen1, R Kirchhoff, H Haacke

  • 1Innere Abteilung, Kreiskrankenhauses Husum.

Deutsche Medizinische Wochenschrift (1946)
|May 10, 1991
PubMed
Summary

Lovastatin, a cholesterol-lowering drug, can rarely cause cholestatic jaundice in patients with hyperlipoproteinaemia. Discontinuation of the drug led to the resolution of jaundice, suggesting a direct effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Subsolar-Mass Binaries in the First Half of Advanced LIGO's and Advanced Virgo's Third Observing Run.

Physical review letters·2022
Same author

Constraints on Cosmic Strings Using Data from the Third Advanced LIGO-Virgo Observing Run.

Physical review letters·2021
Same author

Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.

Living reviews in relativity·2020
Same author

GW190521: A Binary Black Hole Merger with a Total Mass of 150  M_{⊙}.

Physical review letters·2020
Same author

Thickness uniformity measurements and damage threshold tests of large-area GaAs/AlGaAs crystalline coatings for precision interferometry.

Optics express·2019
Same author

Search for Subsolar Mass Ultracompact Binaries in Advanced LIGO's Second Observing Run.

Physical review letters·2019

Area of Science:

  • Pharmacology
  • Hepatology
  • Clinical Medicine

Background:

  • Type IIb hyperlipoproteinaemia is a condition characterized by elevated cholesterol and triglycerides.
  • Dietary management alone was insufficient for this patient's condition.
  • Lovastatin is an HMG-CoA reductase inhibitor used to lower lipid levels.

Observation:

  • A patient with type IIb hyperlipoproteinaemia developed cholestatic jaundice after two months of lovastatin treatment.
  • Biochemical markers indicated significant liver dysfunction, specifically elevated bilirubin.
  • Symptoms and biochemical abnormalities resolved within two weeks of discontinuing lovastatin.

Findings:

  • The case suggests lovastatin can induce cholestatic jaundice, a rare side effect.
  • Hepatocellular damage is a known side effect, but cholestasis is less common.

Related Experiment Videos

  • Exclusion of other causes strengthens the link between lovastatin and jaundice.

    • Implications:

    • Clinicians should be aware of the potential for lovastatin-induced cholestasis.
    • Monitoring liver function is crucial during statin therapy.
    • This case highlights the need for vigilance regarding rare adverse drug reactions.